X. Cabarrocas

461 total citations
12 papers, 374 citations indexed

About

X. Cabarrocas is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Physiology. According to data from OpenAlex, X. Cabarrocas has authored 12 papers receiving a total of 374 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Psychiatry and Mental health, 10 papers in Pathology and Forensic Medicine and 6 papers in Physiology. Recurrent topics in X. Cabarrocas's work include Migraine and Headache Studies (12 papers), Trigeminal Neuralgia and Treatments (10 papers) and Sympathectomy and Hyperhidrosis Treatments (6 papers). X. Cabarrocas is often cited by papers focused on Migraine and Headache Studies (12 papers), Trigeminal Neuralgia and Treatments (10 papers) and Sympathectomy and Hyperhidrosis Treatments (6 papers). X. Cabarrocas collaborates with scholars based in Spain, United Kingdom and France. X. Cabarrocas's co-authors include Julio Pascual, H Massiou, AJ Dowson, Andrew Dowson, Gianni Allais, Gennaro Bussone, Chiara Benedetto, Francesc Peris, A Prusiński and Jesús Llenas and has published in prestigious journals such as Headache The Journal of Head and Face Pain, Cephalalgia and Clinical Therapeutics.

In The Last Decade

X. Cabarrocas

12 papers receiving 353 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
X. Cabarrocas Spain 10 349 263 218 38 26 12 374
R Salonen United States 9 371 1.1× 257 1.0× 204 0.9× 34 0.9× 58 2.2× 15 409
Scott McNeal United States 6 347 1.0× 255 1.0× 221 1.0× 43 1.1× 43 1.7× 6 370
AJ Dowson United Kingdom 7 268 0.8× 149 0.6× 166 0.8× 49 1.3× 24 0.9× 10 325
Mary Hopkins United States 7 323 0.9× 220 0.8× 143 0.7× 40 1.1× 24 0.9× 17 360
Kaihong Jiang United States 6 368 1.1× 219 0.8× 199 0.9× 67 1.8× 39 1.5× 9 405
N T Mathew United States 5 267 0.8× 180 0.7× 134 0.6× 45 1.2× 21 0.8× 6 293
L Pageler Germany 9 362 1.0× 253 1.0× 190 0.9× 29 0.8× 19 0.7× 17 425
P.A. Fowler United Kingdom 9 438 1.3× 277 1.1× 280 1.3× 54 1.4× 70 2.7× 9 501
Bruce Charlesworth United Kingdom 10 214 0.6× 135 0.5× 131 0.6× 42 1.1× 40 1.5× 11 324
CGH Dahlöf Sweden 11 398 1.1× 245 0.9× 189 0.9× 69 1.8× 48 1.8× 11 436

Countries citing papers authored by X. Cabarrocas

Since Specialization
Citations

This map shows the geographic impact of X. Cabarrocas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by X. Cabarrocas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites X. Cabarrocas more than expected).

Fields of papers citing papers by X. Cabarrocas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by X. Cabarrocas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by X. Cabarrocas. The network helps show where X. Cabarrocas may publish in the future.

Co-authorship network of co-authors of X. Cabarrocas

This figure shows the co-authorship network connecting the top 25 collaborators of X. Cabarrocas. A scholar is included among the top collaborators of X. Cabarrocas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with X. Cabarrocas. X. Cabarrocas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Cabarrocas, X., et al.. (2006). Ethanol does not significantly affect the bioavailability of almotriptan: an open, randomized, crossover, single-dose, phase I clinical trial in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics. 44(9). 443–448. 8 indexed citations
2.
Cabarrocas, X., et al.. (2006). Effect of food intake on the bioavailability of almotriptan, an antimigraine compound, in healthy volunteers: an open, randomized, crossover, single-dose clinical trial. International Journal of Clinical Pharmacology and Therapeutics. 44(4). 185–190. 9 indexed citations
3.
Allais, Gianni, et al.. (2006). Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurological Sciences. 27(S2). s193–s197. 54 indexed citations
4.
Dowson, Andrew, et al.. (2004). Almotriptan Improves Response Rates When Treatment Is Within 1 Hour of Migraine Onset. Headache The Journal of Head and Face Pain. 44(4). 318–322. 48 indexed citations
5.
McEwen, John, et al.. (2004). Pharmacokinetics and safety of oral almotriptan in healthy male volunteers. Biopharmaceutics & Drug Disposition. 25(7). 303–311. 9 indexed citations
6.
Cabarrocas, X.. (2004). Meta-Analysis of Oral Triptans: Reply. Cephalalgia. 24(8). 688–689. 1 indexed citations
7.
Llenas, Jesús, et al.. (2002). Almotriptan, a New Anti‐Migraine Agent: A Review. CNS Drug Reviews. 8(3). 217–234. 20 indexed citations
8.
Pascual, Julio & X. Cabarrocas. (2002). Within‐Patient Early Versus Delayed Treatment of Migraine Attacks With Almotriptan: The Sooner the Better. Headache The Journal of Head and Face Pain. 42(1). 28–31. 93 indexed citations
9.
10.
11.
Cabarrocas, X., et al.. (2001). Long‐term Efficacy and Safety of Oral Almotriptan: Interim Analysis of a 1‐Year Open Study. Headache The Journal of Head and Face Pain. 41(1). 57–62. 22 indexed citations
12.
Pascual, Julio, et al.. (2001). Tolerability and Efficacy of Almotriptan in the Long-Term Treatment of Migraine. European Neurology. 45(4). 206–213. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R Salonen Breakdown of academic impact, for papers by Scott McNeal Breakdown of academic impact, for papers by AJ Dowson Breakdown of academic impact, for papers by Mary Hopkins Breakdown of academic impact, for papers by Kaihong Jiang Breakdown of academic impact, for papers by N T Mathew Breakdown of academic impact, for papers by L Pageler Breakdown of academic impact, for papers by P.A. Fowler Breakdown of academic impact, for papers by Bruce Charlesworth Breakdown of academic impact, for papers by CGH Dahlöf
Rankless by CCL
2026